Life Sciences Industry's Transition to Net Zero
The life sciences industry, encompassing pharmaceuticals, medical technology (medtech), contract manufacturing, healthcare distribution, and others, is increasingly focusing on sustainability as a core pillar beyond just compliance. This shift is driven by the industry's innate purpose of providing life-saving therapies, medicines, diagnostics, and devices, alongside a growing recognition of its broader social and environmental impact. The integration of environmental considerations into corporate strategy not only aligns with societal expectations but also presents opportunities for value creation.
Key Aspects of Transitioning to Net Zero
-
Scope 3 Emissions Dominance: The majority of the industry's emissions are classified under Scope 3, which includes indirect emissions from suppliers, customers, and other parties down the value chain. Achieving net zero requires significant collaboration with suppliers and other stakeholders.
-
Balancing Ambition and Investment: Companies are defining ambitious goals aligned with the Science Based Targets initiative (SBTi), assessing risks, benefits, and costs associated with decarbonization efforts.
-
Strategic Roadmap: This involves initiating plans focused on lower-carbon sourcing, green operations, circular business models, sustainable product design, and engagement with key stakeholders across the value chain.
-
Operationalizing Change: This step emphasizes defining governance, building capabilities and processes, and supporting the implementation of decarbonization strategies.
Challenges and Opportunities
-
Scope 3 Emission Reduction: Crafting a successful approach to reduce Scope 3 emissions is crucial, necessitating operational and technological improvements, as well as stakeholder buy-in.
-
Decarbonization Viability and Costs: A typical pharmaceutical company can abate approximately 90% of its total emissions at a cost of around $100 per metric ton of CO₂ by 2040, with the remaining 10% being more challenging to address without innovative solutions.
-
Cost Implications: While cost is a concern, the analysis shows that about 30% of emissions can be abated through levers with positive net present values, leading to cost savings.
Decarbonization Levers
- Purchased Goods and Services: About 50% of total emissions stem from this category. Major decarbonization levers include:
- Raw Materials: Switching to alternative fuels, energy sources, and carbon capture and storage for chemical production.
- Packaging: Redesigning products and materials to reduce volume and source lower-carbon alternatives like recycled or bio-based plastics.
Case Studies
-
Pharmaceutical Companies: Analysis of about 40 pharmaceutical companies reveals that 75% of emissions across the value chain are Scope 3, with 50% attributed to upstream activities. The majority of emissions can be abated at net-zero cost, with significant potential for cost savings through targeted interventions.
-
Medtech Companies: Similar to pharmaceuticals, over 90% of typical players' carbon emissions fall under Scope 3. Strategies for decarbonization focus on improving processes, utilizing natural abatement in the grid, sourcing green electricity, and implementing carbon capture technologies.
Conclusion
The transition to net zero in the life sciences industry presents both challenges and opportunities. By addressing Scope 3 emissions, companies can not only comply with regulations but also enhance their competitive positioning, secure future supply chains, and contribute to global sustainability efforts. Collaboration across the value chain, strategic investment in decarbonization technologies, and continuous innovation are key to achieving this goal.
